CAITLYN O'BRIEN: Open Payments
NPI 1962100446 · STONEHAM, MA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,251 in 127 payments from 10 companies in 2025. Trend: 2023 $1,835 · 2024 $3,126 · 2025 $2,251
Food & beverage: $2,210Education: $41
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. | 27 | $468 |
| Regeneron Healthcare Solutions, Inc. | 24 | $466 |
| AstraZeneca Pharmaceuticals LP | 14 | $343 |
| Novartis Pharmaceuticals Corporation | 17 | $245 |
| GENZYME CORPORATION | 17 | $229 |
| Amgen Inc. | 12 | $213 |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $196 |
| BioCryst US Sales Co., LLC | 2 | $50 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $24 |
| CSL Behring | 1 | $17 |
Products named: DUPIXENT, NUCALA, TEZSPIRE, CUVITRU, Rhapsido, AIRSUPRA, TRELEGY ELLIPTA, ORLADEYO.
Industry payments across MA — which companies pay providers there.
